` FHTX (Foghorn Therapeutics Inc.) vs S&P 500 Comparison - Alpha Spread

FHTX
vs
S&P 500

Over the past 12 months, FHTX has underperformed S&P 500, delivering a return of +6% compared to the S&P 500's +14% growth.

Stocks Performance
FHTX vs S&P 500

Loading
FHTX
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
FHTX vs S&P 500

Loading
FHTX
S&P 500
Difference
www.alphaspread.com

Performance By Year
FHTX vs S&P 500

Loading
FHTX
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Foghorn Therapeutics Inc. vs Peers

S&P 500
FHTX
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Foghorn Therapeutics Inc.
Glance View

Market Cap
296.3m USD
Industry
Biotechnology

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 119 full-time employees. The company went IPO on 2020-10-23. The firm's Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is initially focused on oncology. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, which is evaluating in separate Phase I studies in metastatic uveal melanoma and relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The company is also developing FHD-609, a protein degrader, to treat synovial sarcoma is in phase I study. The firm is also engaged in developing additional programs targeting populations that include selective BRM and selective ARID1B modulators. Foghorn Securities Corporation is its subsidiary.

FHTX Intrinsic Value
4.68 USD
Overvaluation 11%
Intrinsic Value
Price
Back to Top